Evidence for use of anticoagulant class according to renal function
| eGFR (mL/min) . | UFH . | LMWHs . | Warfarin . | Direct oral anticoagulants . |
|---|---|---|---|---|
| >90 | Yes | Yes | Yes | Yes |
| 60-89 | Yes | Yes | Yes | Yes |
| 30-59 | Yes | Yes | Yes | Rivaroxaban dose adjustment |
| 15-29 | Yes | Dose adjustments may be needed; bioaccumulation possible | Yes | Rivaroxaban and dabigatran contraindicated |
| Enoxaparin use with caution | Apixaban use with caution | |||
| <15 | Yes | Use contraindicated outside selected patients with appropriate monitoring | Yes | Rivaroxaban and dabigatran contraindicated; see text for discussion of apixaban |
| eGFR (mL/min) . | UFH . | LMWHs . | Warfarin . | Direct oral anticoagulants . |
|---|---|---|---|---|
| >90 | Yes | Yes | Yes | Yes |
| 60-89 | Yes | Yes | Yes | Yes |
| 30-59 | Yes | Yes | Yes | Rivaroxaban dose adjustment |
| 15-29 | Yes | Dose adjustments may be needed; bioaccumulation possible | Yes | Rivaroxaban and dabigatran contraindicated |
| Enoxaparin use with caution | Apixaban use with caution | |||
| <15 | Yes | Use contraindicated outside selected patients with appropriate monitoring | Yes | Rivaroxaban and dabigatran contraindicated; see text for discussion of apixaban |
Yes indicates there is evidence for use without dose adjustment.